Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2018

View Archived Issues

Phase II results on regorafenib in patients with metastatic osteosarcoma

ChlaDUB1, a Chlamydia effector protein with dual deubiquitination and acetylation activities

Hantavirus cell entry occurs by interaction between protocadherin-1 and viral surface glycoproteins

Mice, MRI and malaria

Claudin changes lead to leaky BBB after stroke

Antibody improves animal ALS symptoms

Patient dosing initiated in phase I study of BAT-4306F

Seres Therapeutics initiates phase II study of SER-287 in ulcerative colitis

FF-10501-01 demonstrates evidence of efficacy in patients with AML and MDS

PARP14 identified as a novel therapeutic target in STAT6-mutant follicular lymphoma

Calithera Biosciences presents early phase II results for CB-839 plus paclitaxel in advanced TNBC

Tychan initiates first-in-human study of TY-014 for Yellow fever

First clinical data presented for TK-006 in breast cancer patients with bone metastasis

E-2814 to begin phase I trials early next year for Alzheimer's disease

FDA places partial clinical hold on phase I studies of MGD-009

Bristol-Myers Squibb and Vedanta collaborate to study Opdivo with VE-800 in advanced cancers

Arctic Pharma discovers lactate dehydrogenase A inhibitors

Sigma1R ligands described by Integrative Research Laboratories Sweden

New P2X4 receptor antagonists synthesized at Bayer

Idorsia Pharmaceuticals patents prostanoid EP2 and/or EP4 receptor antagonists

Taizhou Huayuan Medicinal Tech describes deuterated anxiolytic compounds

C4X Discovery Holdings and e-therapeutics collaboration meets success

Phase I/II trial data of VAL-201 show dose-dependent response in PSA reduction

Avacta enters development alliance with LG Chem Life Sciences

Affimed outlines plans for clinical development and registrational plans for AFM-13

e-therapeutics enters type 2 diabetes research collaboration with Novo Nordisk

Researchers develop new murine model of neurodegeneration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...